David Carbone : Peregrine Pharmaceuticals KOL and IASLC President:
The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation positive non-small cell lung cancer: status in 2016 Daniel S.W. Tan, MBBS, MRCP , Sue S. Yom, MD, PhD , Ming S. Tsao, MD, FRCPC , Harvey I. Pass, MD , Karen Kelly, MD , Nir Peled, MD, PhD , Rex C. Yung, MD, FCCP , Ignacio I. Wistuba, MD , Yasushi Yatabe, MD, PhD , Michael Unger, MD, FACP, FCCP , Philip C. Mack, PhD , Murry W. Wynes, PhD , Tetsuya Mitsudomi, MD , Walter Weder, MD , David Yankelevitz, MD , Roy S. Herbst , David R. Gandara, MD , David P. Carbone, MD, PhD , Paul A. Bunn Jr., MD , Tony S.K. Mok, MDcorrespondenceemail , Fred R. Hirsch, MD, PhD
Publication History Published Online: May 23, 2016 Accepted: May 13, 2016 Received in revised form: May 12, 2016 Received: April 25, 2016
Abstract
Mutations in the epidermal growth factor receptor (EGFR) represent one of the most common “actionable” alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKI) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of osimertinib, a 3rd generation EGFR TKI, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer (IASLC) commissioned consensus statement, key pathologic, diagnostic and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of re-biopsies and use of circulating free DNA (cfDNA) for molecular studies. With the rapid pace of progress in treating EGFR mutant NSCLC, this statement provides a state-of-the-art review of the contemporary issues in managing this unique subgroup of patients.
.. .. Disclosures:
David P. Carbone, MD, PhD reports personal fees from Ariad, personal fees from AstraZeneca, personal fees from Bayer HealthCare, personal fees from Biothera, personal fees from Boehringer Ingelheim, grants and personal fees from Bristol Myers-Squibb, personal fees from Clovis Oncology, personal fees from Genentech/Roche, personal fees from Guardant Health, personal fees from Inivata, personal fees from Janssen Diagnostics, personal fees from Merck, personal fees from Novartis, personal fees from Peregrine Pharmaceuticals, Inc., personal fees from Synta Pharmaceuticals, personal fees from Teva Pharmaceuticals, during the conduct of the study. .. ..
would be nice to have a blood test/assay for these subset group of patients. Hell... maybe even Sunrise study is formulating some data that can get interesting..
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
